These five biotech companies could have a lot of room to run.
Stocks that traded heavily or had substantial price changes on Tuesday: Carlyle Group, Seadrill rise; PG&E, Argenx fall
It's been a good month, but the stock market's looking tired.
The company may have best-in-class autoimmune disease therapy under its roof.
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
The company's lead therapy showed progress in treating an autoimmune disorder.
A major clinical win is boosting the drugmaker's shares today.
Big gains are afoot even as the markets prepare for a flat open.
Medicines to treat the many symptoms of long COVID are in high demand already.